NEUROPROTECTION AND MYELIN REPAIR USING NESTORONE®

Inventors: Regine Sitruk-Ware, New York, NY (US); Michael Maria Helmut Schumacher, Kremlin-Bicêtre (FR); Roberta Brinton, Rancho Palos Verdes, CA (US); Martine El-Etr, Paris (FR); Abdelmouman Ghomari, Antony (FR); Rachida Guennoun, Villejuif (FR)

Assignee: The Population Council, Inc., New York, NY (US)

Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 489 days. This patent is subject to a terminal disclaimer.

Appl. No.: 13/500,008
PCT Filed: Oct. 19, 2010
PCT No.: PCT/US2010/053201
§ 371 (c)(1), (2), (4) Date: May 31, 2012
PCT Pub. No.: WO2011/049948
PCT Pub. Date: Apr. 28, 2011
Prior Publication Data

Related U.S. Application Data
Provisional application No. 61/279,320, filed on Oct. 19, 2009.

Int. Cl.
A61K 31/567 (2006.01)
A61K 31/565 (2006.01)
A61K 31/00 (2000.01)
A61K 31/57 (2000.01)
A61K 31/573 (2000.01)
A61K 31/575 (2000.01)
A61K 31/585 (2000.01)
A61K 45/06 (2000.01)

U.S. Cl.
CPC .......................... A61K 31/565 (2013.01); A61K 31/00 (2013.01); A61K 31/57 (2013.01); A61K 31/573 (2013.01); A61K 31/575 (2013.01); A61K 31/585 (2013.01); A61K 45/06 (2013.01)

Field of Classification Search
CPC ............................ A61K 31/57; A61K 31/565
USPC ............................................. 514/170
See application file for complete search history.

ABSTRACT
Methods for treating neurodegeneration and/or myelination in patients are disclosed comprising treating the patient with a progestin compound which exerts binding to progesterone receptors and elicits progesterone-receptor-induced biologically responsive without interacting with the androgen receptor and without inducing androgen or glucocorticoid biological responses at a dosage sufficient to prevent or reduce neurodegeneration. The progestin compound preferably comprises 16-methylene-17α-aceotxy-19-norpregn-4-ene-3,20-dione, and the methods include combining the progestin compound with an estrogen compound to provide both contraception and treatment for myelin repair and neurodegeneration.

15 Claims, 15 Drawing Sheets
OTHER PUBLICATIONS

Confavreux et al., “Course and Prognosis of Multiple Sclerosis Assessed by the Computerized Data Processing of 349 Patients”, Brain (1980), 103, pp. 281-300.


* cited by examiner
FIG. 1: NESTORONE PROMOTES MYELINATION IN ORGANOTYPIC CEREBELLAR SLICE CULTURES

MBP IMMUNOREACTIVITY
FIG. 3
EFFECT OF PROGESTINS THAT WERE MORE PROLIFERATIVE THAN PROGESTERONE

NESTORONE  NORETHINDRONEL  NORGESTIMATE  PROGESTERONE

CONCENTRATION (M)

-80  -60  -40  -20  0  20  40  60  80

PERCENT INCREASE IN BrdU INCORPORATION VS. VEHICLE CONTROL

IN IMPRESSION VS. VEHICLE CONTROL
FIG. 4  PROGESTINS WITH NO OR ANTAGONISTIC EFFECT ON NEURAL PROGENITOR CELL PROLIFERATION

NORETHINDRONE ACETATE  MEKROXPROGESTERONE ACETATE  PROGESTERONE

PERCENT INCREASE IN Brdu INCORPORATION VS. VEHICLE CONTROL

CONCENTRATION (M)

-80  -60  -40  -20   0    20   40   60

-80  -60  -40  -20   0    20   40   60
FIG. 5
PROGESTINS WITH NEUROPROTECTIVE EFFICACY COMPARABLE TO PROGESTERONE

- THE NEUROPROTECTIVE EFFECT OF PROGESTINS AGAINST GLUTAMATE TOXICITY WAS DETERMINED BY LDH (LACTATE DEHYDROGENASE) ASSAY.
- NEUROPROTECTIVE EFFICIENCY = (Vsample - Vglutamate) / (Vcontrol - Vglutamate)
**FIG. 6A**

percent increase in BrdU incorporation vs. vehicle control

**FIG. 6B**

percent increase in BrdU incorporation vs. vehicle control
**FIG. 6C**

NORETHYNODREL

**PERCENT INCREASE IN BrdU INCORPORATION VS. VEHICLE CONTROL**

**FIG. 6D**

NORETHINDRONE

**PERCENT INCREASE IN BrdU INCORPORATION VS. VEHICLE CONTROL**
FIG. 7A

NEUROPROTECTIVE EFFICACY: LDH DETECTION

FIG. 7B

NEUROPROTECTIVE EFFICACY: LDH DETECTION
**FIG. 7C**

![Graph showing neuroprotective efficacy of levonorgestrel.](image)

**FIG. 7D**

![Graph showing neuroprotective efficacy of norgestimate.](image)
**FIG. 7E**

MEDROXYPROGESTERONE ACETATE

NEUROPROTECTIVE EFFICACY: LDH DETECTION

CONCENTRATION (M)

![Graph](image)

**FIG. 7F**

NORETHINDRONE

NEUROPROTECTIVE EFFICACY: LDH DETECTION

CONCENTRATION (M)

![Graph](image)
**FIG. 8A**

**PCNA**

<table>
<thead>
<tr>
<th></th>
<th>VEHICLE</th>
<th>P4</th>
<th>NESTORONE</th>
<th>LNG</th>
<th>MPA</th>
</tr>
</thead>
<tbody>
<tr>
<td>RATIO OF OPTICAL DENSITY PCNA TO β-ACTIN</td>
<td>*</td>
<td>**</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**β-ACTIN**

**CDC2**

<table>
<thead>
<tr>
<th></th>
<th>VEHICLE</th>
<th>P4</th>
<th>NESTORONE</th>
<th>LNG</th>
<th>MPA</th>
</tr>
</thead>
<tbody>
<tr>
<td>RATIO OF OPTICAL DENSITY CDC2 TO β-ACTIN</td>
<td>*</td>
<td>**</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**FIG. 8B**

![Graphs showing data for different treatments](image)

- **VEHICLE**
- **P4**
- **NESTORONE**

**LNG**

**MPA**

![Bar charts comparing treatments](image)
FIG. 8C

**RATIO OF OPTICAL DENSITY CVα TO β-ACTIN**

<table>
<thead>
<tr>
<th></th>
<th>Vehicle</th>
<th>P4</th>
<th>Nestorone</th>
<th>LNG</th>
<th>MPA</th>
</tr>
</thead>
<tbody>
<tr>
<td>CVα</td>
<td>0.6</td>
<td>1.0</td>
<td>1.2</td>
<td>1.0</td>
<td>0.8</td>
</tr>
<tr>
<td>β-ACTIN</td>
<td>1.0</td>
<td>1.0</td>
<td>1.0</td>
<td>1.0</td>
<td>1.0</td>
</tr>
</tbody>
</table>

**RATIO OF OPTICAL DENSITY Bax TO Bcl-2**

<table>
<thead>
<tr>
<th></th>
<th>Vehicle</th>
<th>P4</th>
<th>Nestorone</th>
<th>LNG</th>
<th>MPA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bax/Bcl-2</td>
<td>0.4</td>
<td>0.4</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
</tr>
<tr>
<td>Bcl-2</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
</tr>
<tr>
<td>β-ACTIN</td>
<td>1.0</td>
<td>1.0</td>
<td>1.0</td>
<td>1.0</td>
<td>1.0</td>
</tr>
</tbody>
</table>
FIG. 9A

RATIO OF OPTICAL DENSITY PCNA TO β-ACTIN

<table>
<thead>
<tr>
<th></th>
<th>PCNA</th>
</tr>
</thead>
<tbody>
<tr>
<td>VEHICLE</td>
<td>0.6</td>
</tr>
<tr>
<td>E2</td>
<td>0.7</td>
</tr>
<tr>
<td>E2+P4</td>
<td>0.8</td>
</tr>
<tr>
<td>E2+NESTORONE</td>
<td><strong>†</strong></td>
</tr>
<tr>
<td>E2+LNG</td>
<td>0.6</td>
</tr>
<tr>
<td>E2+MPA</td>
<td>0.7</td>
</tr>
</tbody>
</table>

PCNA
β-ACTIN
FIG. 9B

PERCENT OF TUNEL-POSITIVE CELLS (APOPTOTIC CELLS)

VEHICLE  E2  E2+P4  E2+NESTORONE  E2+LNG  E2+MPA
NEUROPROTECTION AND MYELIN REPAIR USING NESTORONE®

CROSS-REFERENCE TO RELATED APPLICATIONS


FIELD OF THE INVENTION

The present invention relates to the field of prevention of myelin degeneration and neurodegeneration. More particularly, the present invention relates to the prevention or treatment of degenerative aspects of diseases such as Multiple Sclerosis (MS), Alzheimer’s Disease (AD) and Parkinson’s Disease (PD), as well as for stroke.

BACKGROUND OF THE INVENTION

Multiple Sclerosis (MS) is a progressive and disabling disease of the central nervous system (CNS) affecting more than twice as many women as men (1-4). Evidence suggests that neuronal damage begins early in MS (5), with acute axonal injury already present during active demyelination. However, remyelination is known to occur in MS (6,7), where it protects against axon loss (8). Indeed, no significant axonal damage can be observed in remyelinated plaques (5). Axons become less receptive to remyelination as MS progresses. Furthermore, a stroke is a cerebrovascular incident which also leads to neuronal damage. In an experimental model of transient middle cerebral artery occlusion (MCAO) the infarct volume induced by the occlusion was much larger in mice deprived of progesterone receptor (PR knockout mice) than in control intact mice.

Neuronal damage can also occur in other contexts, such as with a stroke. A stroke is a cerebral vascular incident which results from an interruption in the blood supply to brain cells. Neurons thus can be destroyed because of their sensitivity to oxygen and glucose deprivation, as well as from progressive spreading of nervous tissue damage from an infarct site. There have thus been serious efforts to treat stroke patients to both protect neurons from being destroyed and avoid the spreading of lesions as well as to support regeneration of damaged tissue. Progesterone has previously been identified as an efficient neuroprotective agent. Indeed, progesterone itself is produced at increased rate in brain cells after lesion occurs. Progesterone treatment has also been found to be effective in reducing lesion size following cerebral ischemia in animal models of stroke (18) and has been found to inhibit ischemic brain injury after brain artery occlusion (19).

Progestins such as Nestorone® have been found to exert proliferative and neuroprotective effects in the brain (20,21). Approximately two-thirds of patients with relapsing-remitting MS are women of reproductive age.(9) It is known that a high level of female sex steroids, such as that which occurs during pregnancy, may be responsible for the remission of symptoms in women with MS. This is especially true during the third trimester when estrogen and progesterone (PROG) levels peak, while the relapse rate increases in the post-partum period.(9)

Women with MS experience changes in their MS symptoms related to pregnancy, the postpartum period, or menopause. In a study conducted in Sweden (10), 40% of the 148 women with MS who were interviewed reported worsening of MS symptoms related to menopause, and more than a fourth of the younger women reported decreased symptoms during pregnancy. Every third woman reported increased symptoms after delivery, suggesting that the sex steroids play a role in the protection (when present in high levels during pregnancy) or worsening of the disease (when they decrease after delivery or at menopause).

An effective treatment strategy for conditions such as MS must also include therapeutic agents that reverse axon demyelination in order to prevent irreversible axon loss. Estrogen and progesterone, female sex hormones, may have beneficial effects on MS and neuroprotection.

The neurodegenerative process of several CNS diseases, including Multiple Sclerosis (MS), Alzheimer’s Disease (AD) and Parkinson’s Diseases (PD) involve neuroinflammation as well as neurodegeneration, and their frequency increases in women after menopause. Similar neurodegenerative processes are also present in stroke patients, or those who have suffered the effects of a cerebrovascular incident. In primary hippocampal neuron cultures treated with 17β-E2 and progestins, alone and in combination, 48 hours before glutamate insult, estradiol, progestrone, and 19-norprogestrone, alone or in combination, protected against glutamate toxicity. In contrast, medroxyprogesterone acetate (MPA) failed to protect against glutamate toxicity. Not only was MPA an ineffective neuroprotectant, but it attenuated the estrogen-induced neuroprotection when coadministered (11). These results may have important implications for the maintenance of neuronal function during menopause and aging and for protection against neurodegenerative diseases such as Alzheimer’s disease by selecting the appropriate molecules for hormone therapy.

Progesterone receptor (PR) expression and regulation of neural progenitor cell proliferation was investigated using NPC derived from adult rat brain. Progesterone mediated neural progenitor cell (NPC) proliferation and concomitant regulation of mitotic cell cycle genes is a potential novel therapeutic target for promoting neurogenesis in the mammalian brain (12).

SUMMARY OF THE INVENTION

In accordance with the present invention, these and other objects have now been realized by the discovery of a method for treating neurodegeneration in a patient comprising treating the patient with a pharmaceutically effective dosage of a progestin compound which exerts binding to progesterone receptors and elicits progesterone-receptor-induced biological responses without interacting with the androgen receptor and without inducing androgen or glucocorticoid biological responses, the pharmaceutically accepted dosage being 5 mg/day or less, whereby neurodegeneration is prevented or reduced. In a preferred embodiment, the pharmaceutically effective dosage of Nestorone® comprises from 100 to 450 µg/day. Preferably, the pharmaceutically effective dosage comprises a continuous dosage provided to the patient. In another embodiment, however, the pharmaceutically effective dosage comprises an interrupted dosage provided to the patient. Preferably, the interrupted dosage comprises three weeks on the dosage followed by one week off the dosage.

In accordance with one embodiment of the method of the present invention, the methods includes simultaneously treating the patient with an estrogen compound. Preferably,
the estrogen compounds comprises estradiol, and in a preferred embodiment the estradiol comprises from about 10 to 150 µg/day.

In accordance with another embodiment of the method of the present invention, the pharmaceutically effective dosage of the progestin compound comprises a transdermal dosage form.

In accordance with another embodiment of the method of the present invention, the progestin compound is selected from the group consisting of Nestorone®, 18-methyl Nestorone®, nomegestrol acetate, trimgestone, norgestimate, dienogest, drosiprenone, chlormadinone acetate, promegestone, retroprogesterone, and 17-hydroxyprogesterone. In a preferred embodiment, the progestin compound comprises nomegestrol acetate, and the pharmaceutically effective dosage comprises from 2.5 to 5 mg/day. In another embodiment, the progestin compound comprises trimgestone, and the pharmaceutically effective dosage comprises from about 0.5 to 1 mg/day. In accordance with another embodiment, the progestin compound comprises dienogest, and the pharmaceutically effective dosage comprises from about 2 to 3 mg/day. In accordance with another embodiment, the progestin compound comprises drosiprenone, and the pharmaceutically effective dosage comprises about 3 mg/day. In another embodiment, the progestin compound comprises chlormadinone acetate, and the pharmaceutically acceptable dosage comprises about 5 mg/day.

In accordance with another embodiment of the method of the present invention, the treating comprises providing the predetermined dosage in a transdermal form selected from the group consisting of transdermal gels, transdermal solutions, transdermal sprays, and transdermal patches. In another embodiment, the method comprises providing the predetermined dosage in a transdermal form selected from the group consisting of intravaginal tablets, intravaginal gels, and intravaginal rings.

In accordance with another embodiment of the method of the present invention, the method includes treating comprising a subcutaneous implant.

In accordance with the present invention, a method is provided for treating neurodegeneration in post-menopausal women comprising treating the post-menopausal women with a pharmaceutically effective dosage of a progestin compound which exerts binding to progestosterone receptors and elicits progestosterone-receptor-induced biological responses without interacting with the androgen receptor and without inducing androgenic or glucocorticoid biological responses at a dosage sufficient to prevent or reduce neurodegeneration in post-menopausal women, and simultaneously providing a predetermined dosage of natural estradiol. In the preferred embodiment of this method of the present invention, the progestin compound comprises Nestorone®, and preferably is provided in an amount of between about 100 and 450 µg/day. In a preferred embodiment, the estradiol is provided in amounts of from about 10 to 150 µg/day.

In one embodiment of this method of the present invention, the pharmaceutically effective dosage of the progestin compound comprises a transdermal dosage form selected from the group consisting of transdermal gels, transdermal solutions, transdermal sprays, transdermal patches, intravaginal tablets, intravaginal gels, and intravaginal rings.

In accordance with the present invention, a method is provided for treating neurodegeneration exhibited in a condition selected from the group consisting of multiple sclerosis, Alzheimer's disease, Parkinson's disease, and stroke in a patient comprising treating the patient with a pharmaceutically effective dosage of a progestin compound which exerts binding to progestosterone receptors and elicits progestosterone receptor-induced biological responses with interacting with the androgen receptor and without inducing androgenic or glucocorticoid biological responses wherein the pharmaceutically effective dosage comprises 5 mg/day or less, whereby neurodegeneration is prevented or reduced thereby. Preferably, the progestin compound comprises Nestorone®. In another embodiment, the progestin compound is selected from the group consisting of 18-methyl Nestorone®, nomegestrol acetate, trimgestone, norgestimate, dienogest, drosiprenone, chlormadinone acetate, promegestone, retroprogesterone, and 17-hydroxyprogesterone.

In accordance with the present invention, preliminary studies in tissue culture and animal models have shown that a particular class of progestin compounds, which includes Nestorone® (NES), a synthetic progestin derived from 19-norpregesterone, with no androgenic, estrogenic, or glucocorticoid actions, have been shown to have greater beneficial effects on remodeling in in vitro models as compared, for example, to progesterone, as well as to certain other progestin compounds. There are bioassays comparing the effects of different progestins. Nestorone® has no androgenic or estrogenic action at all and also does not elicit a glucocorticoid effect except at doses 2,000-fold the therapeutic dose. The other progestins such as levonorgestrel and MPA induce androgenic responses, MPA induces both androgenic and glucocorticoid responses, and norethindrone and norethisterone exert with androgenic and estrogenic responses. Furthermore, in recent studies, NES has also been shown to stimulate proliferation of neural progenitor cells, again even higher than progesterone itself. These results have led to the discovery of a method for treating neurodegeneration in a patient comprising treating the patient with a predetermined dosage of a progestin compound which exerts binding to progestosterone receptors and elicits progestosterone-receptor-induced biological responses without interacting with the androgen receptor and without inducing any androgenic or glucocorticoid biological responses at a dosage sufficient to prevent or reduce neurodegeneration. In connection with this embodiment, the patient can comprise a male or female patient. In addition, in accordance with the present invention, a method for treating neurodegeneration in a patient comprises treating the patient with a pharmaceutically effective dosage of a progestin compound which exerts binding to progestosterone receptors and elicits progestosterone-receptor-induced biological responses without interacting with the androgen receptor and without inducing any androgenic or glucocorticoid biological responses at a dosage sufficient to prevent or reduce neurodegeneration, in conjunction with an estradiol compound. In this embodiment, the patient is preferably a female patient. The specified progestin compounds of this invention can be applied in various ways, both orally and non-orally, including gels, patches, vaginal rings for women, or the like, in a wide range of dosages, ranging broadly from as low as about 30 µg/day absorbed by the patient, such as by the use of implants or the like, up to about 5 mg/day, such as by the use of tablets or other such means of up to 3 to 5 mg. Similarly, in the case of estrogens, the amount delivered can range from as low as 1 up to about 2,000 µg per day. It is also believed that a treatment for menopausal therapy including daily doses of NES between about 100 and 400 µg/day, along with an estrogen, specifically estradiol in amounts of from 50 to 150 µg/day in gel formulations, will result in unexpectedly improved prevention or reduction in neurodegeneration and/
or in myelin degeneration. This treatment can also be carried out vaginally, such as by use of a vaginal ring containing these compositions. The delivery can be either continuous or sequential, such as sequential delivery of three weeks continuous delivery followed by one week of cessation of delivery.

It has further been discovered that these treatments can not only be applied to post-menopausal women, but can be useful for the treatment in preventing or reducing neurodegeneration in conditions such as MS, AD, PD, and in connection with stroke.

The primary focus of the present invention relates to methods for treating neurodegeneration or myelin degeneration in patients, both male and female. This primarily comprises treating these patients with pharmacologically effective dosages of specific progestins such as Norgestrel®, at dosage levels of 10 to 450 μg/day and up to 5 mg/day or less in order to prevent or reduce neurodegeneration.

In one embodiment of the present invention, however, the invention is directed specifically towards female patients. In one aspect of this treatment, the progestin is combined with an estrogen compound, such as estradiol, so that in general both prevention or reduction in neurodegeneration and/or myelin repair is effected along with either contraception or hormone therapy. Thus, in connection with young premenopausal women of fertile age, with or without neurodegenerative conditions such as MS, AD, PD, stroke, or the like, contraception is ensured, while in post-menopausal women, again with or without these neurodegenerative disorders, hormone therapy treatment can also be effected. Thus, in addition to contraception and/or hormone therapy treatment, these combinations of compositions can be used to prevent or reduce relapses in MS in women either of reproductive age or post-menopausally or during the post-partum period.

In a preferred embodiment, this is accomplished by administering a progestin, such as those discussed above, preferably Norgestrel®, and most preferably in the form of a vaginal ring to administer this composition in the form of the specific daily doses discussed above.

In the case of post-menopausal women, in one embodiment of the present invention, compounds of this invention are administered in the form of a transdermal gel, once again preferably including the combination of both the progestin, such as Norgestrel®, and estradiol. It is thus anticipated that this method can prevent or treat neurodegeneration in clinical situations of these medical conditions such as MS, AD, PD, and stroke. Preferably, the daily doses of the progestin, such as Norgestrel®, will range from 100 to 450 μg/day, again with or without associated estrogen therapy in such post-menopausal women. The progestin dosages can be administered either continuously or interrupted by sequences of no treatment in order to allow for full efficacy in neuropsychiatric and to induce endometrial shedding.

On the other hand, in connection with the treatment of young pre-menopausal women of fertile age, in one embodiment the present invention provides continuous long-term administration of the progestin, such as Norgestrel®, at daily dosage rates of about 200 μg/day, preferably in the form of a vaginal ring. Again, this both insures contraception with or without treatment of neurodegenerative conditions such as MS and the like. Furthermore, in view of the potent anti-ovulatory action of compounds such as Norgestrel® itself, the long-term administration of these dosages is adapted to prevent pregnancies as well as to prevent relapses from MS. Thus, in accordance with this invention, a new contraceptive agent is disclosed which has additional health benefits as opposed to all of the current estrogen-progestin contraceptives which do not contain these progestins with neuroprotective properties to be used in most women.

In accordance with a preferred embodiment of one aspect of the present invention, a composition is provided which includes a daily dose of Estrogen® for transdermal application, preferably in the form of a gel, containing between about 1 mg and 4.5 mg of transdermally applied Norgestrel® (absorption of 10% resulting in about 100 to 450 μg/day of Norgestrel®) which can be given alone, or which can be combined, preferably before use, for menopausal therapy, with estradiol, transdermally applied at from 0.5 to 1.5 mg, or 50 to 150 μg/day. In a preferred embodiment in which a vaginal ring is employed, the daily dose of Norgestrel® is between about 100 and 500 μg/day either alone, or in combination with estradiol, preferably at doses of between 10 and 50 μg/day. In this embodiment these dosages can be applied either continuously, or sequentially, such as on a regimen of three weeks on and one week off.

In accordance with another embodiment of the present invention, post-menopausal women, with or without neurodegenerative disorders, can be treated to induce neural progenitor cell proliferation by providing daily dosage units comprising the progestins discussed above, including Norgestrel®, in dosage amounts sufficient to induce neural progenitor cell proliferation.

The present invention also clearly has a general application for both males and females specifically for treating neurodegeneration or myelin degeneration in a patient. This method thus includes treating the patient with a pharmacologically effective dosage, preferably 5 mg/day or less, of the progestins of the present invention, preferably Norgestrel®, so as to prevent or reduce neurodegeneration. In the preferred embodiment, the amount of Norgestrel® utilized will constitute a daily dose of from between 100 to 300 μg/day, preferably about 200 μg/day.

The method of administering these doses of progestins, such as Norgestrel®, for example, can comprise non-oral administration. Non-oral administration can include transdermal administration by means of gels, sprays, transdermal patches, or in the form of vaginal rings or implants. Oral administration of the progestins of the present invention which are orally active, can take place in the form of tablets, capsules, cachets, dragees, pills, pellets, granules, powder, solutions, emulsions, suspensions, and the like.

As for the specific progestin compounds which can be used in accordance with this invention, these can include progestins such as Norgestrel®, as well as 18-methyl Norgestrel®, nomegestrol acetate, trimetadest, as well as non-androgenic progestins, such as norgestimate, dienogest, drospirenone, chlorogestrel acetate, progesterone, progestosterone, and 17-hydroxyprogesterone. In general, the method of the present invention can thus be utilized for the prevention or reduction of neurodegeneration and/or for myelin degeneration, and/or for the treatment of conditions such as MS, AD, PD, or stroke.

As discussed above, the daily dose of the progestins in accordance with the present invention is selected in order to exert binding to progesterone receptors and to elicit progesterone-induced biological responses without inducing either androgenic or glucocorticoid biological responses.

In accordance with a preferred embodiment of the present invention, a new contraceptive agent is provided with additional health benefits, as opposed to all current estro-pro-
gestin contraceptives, which do not contain such progestin with neuroprotective properties, to be used in most women.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a graphical representation comparing Norethisterone® with progesterone and promoting dose-dependent myelination;

FIG. 2 is a graphical representation comparing myelination with Norestosterone® lysosceitin, and RU486;

FIG. 3 is a graphical representation of the effect of progestins on the proliferation of progenitor cells;

FIG. 4 is a graphical representation of various progestins on the proliferation of progenitor cells;

FIG. 5 is a graphical representation of various progestins regarding neuroprotective efficacy;

FIG. 6A is a graphical representation comparing the NPC regeneration of norgestemate with progesterone;

FIG. 6B is a graphical representation comparing NPC regeneration with Norestosterone® compared to progesterone;

FIG. 6C is a graphical representation comparing NPC regeneration for norethynodrel compared to progesterone;

FIG. 6D is a graphical representation comparing NPC regeneration for norethindrone compared to progesterone;

FIG. 7A is a graphical representation comparing neuroprotective efficacy for Norestosterone® with progesterone;

FIG. 7B is a graphical representation comparing neuroprotective efficacy for norethynodrel with progesterone;

FIG. 7C is a graphical representation comparing neuroprotective efficacy for levonorgestrel with progesterone;

FIG. 7D is a graphical representation comparing neuroprotective efficacy for norgestimate with progesterone;

FIG. 7E is a graphical representation comparing neuroprotective efficacy for medroxyprogesterone acetate with progesterone;

FIG. 7F is a graphical representation comparing neuroprotective efficacy for norethindrone with progesterone;

FIG. 8A is a graphical representation comparing NPC proliferation in cell viability with various progestins;

FIG. 8B is a graphical representation comparing NPC proliferation in cell viability with various progestins;

FIG. 8C is a graphical representation comparing NPC proliferation in cell viability with various progestins;

FIG. 9A is a graphical representation of PCNA expression of various progestins; and

FIG. 9B is a graphical representation of percent of TUNEL-positive cells.

DETAILED DESCRIPTION

The present invention is most particularly based upon the discovery of the particular properties of certain progestins. Most particularly, these progestin compounds exert binding to progesterone receptors and elicit progesterone-receptor-induced biological responses without interacting with the androgen receptor and without inducing their androgenic or glucocorticoid biological responses at a dosage sufficient to prevent or reduce neurodegeneration, and which dosage is nevertheless 5 mg/day or less. These progestins thus include Norestosterone®, 18-methyl Norestosterone®, nomegestrol acetate, trimestene, norgestimate, norethisterone, ethynodrel, desogestrel, clomethindione acetate, progestenate, retroprogesterone, and 17-hydroxyprogesterone. Thus, this class of progestins includes progesterone and levonorgestrel, which interacts with the androgen receptor, and which require a dosage of greater than 5 mg/day, and generally up to 10 mg/day or more, for efficacy. The progestin compounds of the present invention can also include progestin compounds which exert binding to progesterone receptors and elicit progesterone-receptor-induced biological responses without inducing their androgenic or glucocorticoid biological responses.

We have set forth herein some presently preferred dosages for the progestins, such as Norestosterone®, which is highly preferred for use in connection with the present invention. It is, however, within the skill of those in the pharmaceutical art to determine with routine experimentation what dosage of each of these progestins will be needed, depending on the particular route of administration, to deliver such an effective dose. However, while there are such variations as set forth below, it has been found that all of these progestin compounds of the present invention can be effectively utilized at dosages of 5 mg/day or less, which is considerably less than effective dosages of compounds such as progesterone. It is understood that the dosage of each of these progestins is used, such as Norestosterone®, administered in vivo may be dependent on the age, sex, health and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment, and the nature of the pharmaceutical effect desired. The ranges of effective doses provided herein are not intended to be limiting and represent preferred dose ranges with the overall lower dosage range of 5 mg/day or less hereof. However, the most preferred dosages within that overall range may be tailored to the individual subject, as is understood and determinable by one skilled in the relevant art. See, e.g., Berkow et al., eds., The Merck Manual, 16th Ed., Merck & Co., Rahway, N.J. (1992); Goodman et al., eds., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 4th Ed., Pergamon Press Inc., Elmsford, N.Y. (1990); Katzung, Basic and Clinical Pharmacology, Appleton & Lang, Norwalk, Conn. (1992); Avery's Drug Treatment Principles and Practice of Clinical Pharmacology and Therapeutics, 3rd Ed., ADIS Press Ltd., Williams & Wilkins, Baltimore, Md. (1987); Faddis, Pharmacology, Little, Brown & Co., Boston, Mass. (1985); Remington's Pharmaceutical Services, 17th ed., Alphonzo R. Genaro, Mack Publishing Company, Easton, Pa. (1985); which references are entirely incorporated here by reference thereto.

The dosages can be determined by a clinician using conventional dose escalation studies. It can be expected to be within the above preferred ranges. Furthermore, while this discussion has specifically referred to the highly significant progestin component of the present invention, it can, of course, also apply with equal force to the estrogen component hereof.

In addition, by the term "pharmacologically effective" it is meant that amount which is sufficient to effect the desired changes in the subject. The amount will vary depending upon such factors as the potency of the particular drug, the desired therapeutic effect, and the time span for which the method of application is intended to provide treatment. Those skilled in the pharmaceutical arts will be able to determine both toxic levels and the minimum effective doses of the drug in accordance with standard procedures. For instance, a proper dosage form can be prepared by measuring the in vivo rate or elution of a given drug by standard analytic techniques, e.g., spectroscopic or radioimmunoassay analysis. In vitro diffusion of the drug from a delivery device of the present invention may be determined, for example, by the methods disclosed in Chien et al., J. Pharm. Sci., 63, 365 (1974) or by the methods described in U.S. Pat. No. 3,710,795, the disclosures of which are incorporated by reference herein.

The applicants have discovered that these specific progestin compounds have unexpected properties in terms
of their myelination and also for the treatment of neurodegeneration, and in particular treatment of conditions such as MS, AD, PD, and stroke, and furthermore that these unexpected properties can be obtained in conjunction with treatment, of contraceptive action with these compounds known to be useful for that purpose.

A particular preferred use of the progestins of the present invention is thus in conjunction with an estrogen compound. By estrogen compound one of skill in the art will appreciate that the estrogen can be selected from the group consisting of estradiol, ethinyl estradiol, estradiol sulfimates, estradiol valerate, estradiol acetate, estradiol benzoate, estrone, estriol, estriol succinate, and conjugated estrogens including conjugated equine estrogens such as estrone sulfate, 17β-estradiol sulfate, 17α-estradiol sulfate, equinulin sulfate, 17β-dihydroequinulin sulfate, 17α-dihydroequinulin sulfamate, 17β-dihydroequinulin sulfinate, 17α-dihydroequinulin sulfonic acid, 17α-hydroequinulin sulfoxide, estriol, or mixtures thereof. Most preferred is estradiol.

The combination of progestins with estrogens for contraceptive purposes is widely known. Indeed, since progestins alone cannot normally be used for the purpose of controlling the bleeding patterns in women, nor for postmenopausal use, it has become necessary to combine these progestins with estrogens for these purposes. Furthermore, while the primary thrust of the present invention is based upon the discovery that certain progestins as described herein possess unexpectedly superior properties in connection with neuroprotection and myelination, and the addition of an estrogen is not necessarily for assisting in that objective, it is also possible that the use of certain estrogens in combination with these progestins provides even greater unexpected results in terms of neuroprotection, or neuroregeneration and myelin repair.

In experiments conducted in organotypic neonatal rat or mouse cerebellar slice culture, progesterone accelerated axon myelination (13,14). In a study conducted in accordance with this invention, both progesterone (PROG) and Nestorone® (NES) were found to promote dose-dependent myelination, as measured by myelin basic protein (MBP) immunoreactivity. NES was found to be significantly more potent than PROG, as NES at 20 µM was as active as PROG at 50 µM (Fig. 1). It was also shown that the intracellular progesterone receptor (PR) may mediate the promyelinating actions of PROG as the treatment did not increase myelination in cerebellar slices from PR knockout mice.

In the same animal model, cerebellar slices were cultured until myelination was complete, then incubated overnight with l-lysine (LYSO) to produce demyelination utilizing a known technique (15) followed by 3 days of incubation with NES 20 µM in fresh culture medium (10% penetration in slices). Slices were immunostained for MBP. As shown in Fig. 1, NES produced remyelination. MBP staining intensity was measured in cerebellar slices after completion of normal myelination, after demyelination with l-lysine, and after 3 days of incubation with NES at 20 µM, RU486 at 10 µM, or NES+RU486. NES-stimulated remyelination of lysine-inhibited cerebellar slices may involve the classic progesterone receptor (PR), as RU486 appeared to inhibit NES activity in this model (Fig. 2).

According to the above described in vitro studies, it appears that myelination/remyelination action of NES may be mediated by the progesterone receptors (PR). Thus, NES, which is a potent agonist of PR and one of the most potent progestins without androgenic activity that induces PR-related biological responses, appears to improve myelin regeneration even better than progesterone, and this can become a treatment of the diseases or conditions associated with demyelination.

In postmenopausal women, the increase in neurodegenerative diseases has been related to the lack of estrogen and little attention has been paid to the role of progesterone. Study of the proliferation of neural stem cells in a rodent model showed that in the subventricular zone of the brain these cell rapidly divide and give rise to neuroblasts that will become interneurons. Progesterone increases the proliferation of these progenitor cells. Among various progestins tested for cell proliferation, Nestorone® is as effective or even more effective than progesterone. Norethynodrel and norgestimete were also more proliferative than progesterone (Fig. 3). However other progestins were either less effective than progesterone (NET, LNG) or antagonistic (MPA, NETA) on the proliferation (Fig. 4).

The effect of NES and other progestins on CNS plasticity and the neuroprotective efficacy against glutamate toxicity has also been evaluated. LDH was measured, as a well accepted assay, to determine such effect after exposure of the cells to glutamate, and the neuronal viability was assessed under the action of various progestins. Fig. 5 shows that three progestins have comparable effect to progesterone and at 10-7M NES, and PROG exerted the higher efficacy while LNG, an androgenic progestin, was more active than PROG at lower doses.

**EXAMPLE 1**

In vitro studies were carried out to determine neural progenitor cell (NPC) regeneration in rnts. 5-Bromo-2-deoxyuridine (BrdU) chemiluminescence enzyme-linked immunosorbant assay (ELISA) and the results are shown in Figs. 6A-D. Cell proliferation was determined by S phase incorporation of BrdU. After 4 to 6 hours starvation (medium without supplements), rNPCs were loaded with 10 µM BrdU in the presence or absence of bFGF and varying concentrations of P4 or test progestins in unsupplemented maintenance medium for 1d. The rNPCs were then processed as described previously (1, 14). After subtracting the value of the blank (without BrdU loading), data were analyzed using a one-way ANOVA, followed by a Neuman-Keuls post hoc test. These results demonstrate that at 24 hours norgestimete was more potent in cell proliferation than progesterone at all concentrations. Nestorone® and progesterone were comparably efficacious at their EC100 concentrations. Norethynodrel produced comparable effects to progesterone at the low nanomolar range but was significantly more efficacious than progesterone at high nanomolar ranges. Norethindrone was less effective than progesterone and levonorgestrel and norethindrone acetate exerted minimal or no effect on proliferation while medroxyprogesterone acetate (MPA) significantly inhibited proliferation at multiple concentrations.

**EXAMPLE 2**

Comparisons of neuroprotection against neurodegenerative insults were carried out. Efficacy was determined in connection with the protection of primary hippocampal neurons against degeneration induced by excitotoxic glutamate. Hippocampal neuronal cultures grown on 90-well culture plates for 7d in vitro were pretreated with vehicle alone or test compounds, followed by exposure to 200 µM glutamate as previously described (13). At glutamate exposure, cultures were washed with HEPES-buffered saline.
solution and replaced with fresh NBM containing the test.

EXAMPLE 3

The generalized ability of the above in vitro findings to
the in vivo condition were investigated. Analyses of NPC
proliferation in rats and cell viability were conducted in
three-month-old Sprague-Dawley ovariectomized female
rats with various of the progestins. Cell cycle protein
expression was determined by Western blot analysis, and
the results as shown in FIG. 8A indicated that Nestorone®
appeared to be slightly superior to progesterone in terms of
increased PCNA expression at the protein level. Levonorg-
estrel and MPA, on the other hand, had no significant effect
on PCNA expression, while CDC2 protein expression was
significantly increased by both progesterone and Nesto-
rone®, but not with levonorgestrel and MPA. In order to
assess the total number of BrdU+ cells, the contralateral
hippocampal hemisphere used for protein analysis was fixed
and processed by FACS analysis. The total number of
BrdU+ cells per each hippocampus was determined and
normalized to that of vehicle control. The results are shown
in FIG. 8B demonstrating that Nestorone® was slightly
superior to progesterone in significantly increasing BrdU+ cell
numbers while levonorgestrel was comparable to progester-
one while MPA had no significant effect on cell proliferation
in vivo. In order to measure cell viability in terms of
promotion of mitochondrial function and reduction in oxi-
dative damage expression of the alpha subunit of ATP
synthase-Complex V (Coxa) of the mitochondrial oxidative
phosphorylation pathway was assessed by Western blot
analysis. The results as shown in FIG. 8C demonstrate that
Nestorone® increased CVA expression even greater than
progesterone and levonorgestrel while again MPA exerted
no significant effect on CVA expression levels.

EXAMPLE 4

The effects of various progestins on apoptosis was studied
using Western blot analysis to determine the expression level
of Bax, an apoptosis mediator by translation to the mito-
chodria to release apoptotic factors such as cytochrome c
and Bcl-2. The ratio of Bax to Bcl-2 was used as an indicator
of in vivo apoptotic activity. The results obtained dem-
strated that both progesterone and Nestorone® had no effect
on the ratio of Bax/Bcl-2 expression, while levonorgestrel
and MPA significantly increased the ratio demonstrating a
pro-apoptotic effect therein.

EXAMPLE 5

The impact of the combination of 17β-estradiol (E2) and
various progestins on neurogenesis and cell viability in vitro
was also carried out. Young adult ovariectomized female
Sprague Dawley rates were thus divided into six groups and
received injection of either E2 alone or E2 combined with
one of the progestins. Hippocampi were isolated 24 hours
later for Western blot analysis and flow cytometry to deter-
mine the impact of treatment on cell viability and neuro-
genesis respectively. The expression level of PCNA was
assessed to determine the impact of the treatment com-
ponds on entry into the cell cycle required for neurogen-
esis. The results demonstrated that Nestorone® plus E2
induced the greatest magnitude of PCNA expression and
neural progenitor cell proliferation (see FIG. 9A).

Importantly, Nestorone®, in combination with estradiol,
did not increase neural progenitor cell death as evidenced by
no increase in TUNEL positive cells, a marker for apoptosis.
In contrast, both MPA and levonorgestrel, in combination with
estradiol, significantly increased apoptosis, as evidenced
by an increase in TUNEL positive cells (see FIG. 9B). As noted above, both MPA and levonorgestrel increased
cell proliferation.

The present invention provides a method of stimulating
neuroregeneration and possibly inhibiting and reversing
neurodegenerative disorders such as MS or AD, as well as
stroke.

The proposed method comprises reversing the myelin
degeneration with a dose of NES in the range of about 100
to 450 μg per day administered either by a vaginal ring or in
a vaginal gel alone or in association with estradiol.

In another embodiment of the invention, NES, or a
progestin without androgenic or glucocorticoid properties, is
administered to postmenopausal women who receive low
doses of estrogen as hormone therapy and a possible pre-
vention of neurodegeneration.

The present invention pertains to the discovery that NES
is more active than progesterone to stimulate progenitor
neuronal cells as well as the regeneration of myelin. A
farther core aspect of the invention is that agents capable of
binding to the progesterone receptors and inducing PR-
induced biological responses, would be effective in prevent-
ing or reversing neurodegeneration, for women in reproduc-
tive age as well as postmenopausal, women.

The term “Nestorone®” (NES) refers to a 19-norpro-
sterone derivative that exerts a potent progestational and
anti-inflammatory action and does not carry androgenic or
estrogenic or glucocorticoid actions at therapeutic levels (16). In
particular, it refers to 16-methylene-17α-acetoxy-19-nor-
pregn-4-ene-3,20-dione, which was formerly referred to as
ST1455.

The term “DDU” herein refers to daily dosage units
wherein the DDU is in oral formulation for other 19-norpro-
sterone derivatives that are active orally (not NES), or in
a vaginal (gel or ring) or transdermal formulation (gel,
spray).

The term “contraceptive agent” used herein refers to
medications administered in order to prevent or reduce the
likelihood of pregnancy.

The present invention is based on the fact that progester-
one stimulates myelin repair. These effects are mediated by
progesterone receptors (PR). The present invention reveals
that NES is more active than PROG and can regenerate
myelin at doses that also exert contraceptive efficacy.

The present invention also reveals that progenitor cells of
neuronal tissue proliferate when cultured with progesterone
and moreover with NES at lower doses indicating a higher
activity.

Also, progesterone and some progestins, especially NES
and also norgestimate (a non-androgenic gonane) and nor-
ethynodrel (an estrane progestin with estrogenic activity) stimulate progenitor cell proliferation.

Based on the superior effect of NES on myelin stimulation as well as on neuroregeneration, it is a purpose of the present invention to improve the medical conditions of multiple sclerosis and neurodegenerative disorders and at the same time providing a contraception in women of fertile age or a hormonal therapy in women who are in the menopause.

Although the invention herein described with reference to particular embodiments, it is to be understood that these embodiments are merely illustrative of the principles and applications of the present invention. It is therefore to be understood that numerous modifications may be made to the illustrative embodiments and that other arrangements may be devised without departing from the spirit and scope of the present invention as defined by the appended claims.

INDUSTRIAL APPLICABILITY

The methods of treating neurodegeneration or myelination which are depicted in this application are particularly useful in the form of a non-oral dosage form of a specified progestin, such as Nestorone®, either alone or in combination with an estrogen, such as estradiol. This composition is used in the form of a transdermal product, such as a gel, solution, spray or patch, or in the form of a vaginal ring, which can thus be used by a patient to reduce neurodegeneration and when combined with the estrogen, to also be used for contraception and/or hormone replacement therapy.

REFERENCES


The invention claimed is:

1. A method for remyelination in a patient comprising treating said patient with a pharmaceutically effective dosage of a progesterone compound which exerts binding to progesterone receptors and elicits progesterone-receptor-induced biological responses without interacting with the androgen receptor and without inducing androgen or glucocorticoid biological responses selected from the group consisting of 16-methylene-17α-acetoxy-19-norpregn-4-ene-3,20-dione, 18-methyl Nestorone, nomegestrol acetate, trimgestone, and promegestone, said pharmaceutically effective dosage being an effective amount for remyelination comprising 100 to 450 µg/day, whereby neurodegeneration is reduced.
2. The method of claim 1 including simultaneously treating said patient with an estrogen compound.
3. The method of claim 1 wherein said estrogen compound comprises estradiol.
4. The method of claim 3 wherein the dosage of said estradiol comprises from about 10 to 150 µg/day.
5. The method of claim 1 wherein said pharmaceutically effective dosage comprises a continuous dosage provided to said patient.
6. The method of claim 1 wherein said pharmaceutically effective dosage comprises an interrupted dosage provided to said patient.

7. The method of claim 6 wherein said interrupted dosage comprises three weeks on said dosage followed by one week off said dosage.

8. The method of claim 1 wherein said pharmaceutically effective dosage of said progestin compound comprises a transdermal dosage.

9. The method of claim 1 wherein said treating comprises providing said predetermined dosage in a transdermal form.

10. The method of claim 9 wherein said transdermal form is selected from the group consisting of transdermal gels, transdermal solutions, transdermal sprays, and transdermal patches.

11. The method of claim 9 wherein method of treating comprises a transdermal product selected from the group consisting of intravaginal tablets, intravaginal gels, and intravaginal rings.

12. The method of claim 1 wherein said method of treating comprises a subcutaneous implant.

13. The method of claim 1 wherein said progestin compound comprises 16-methylene-17α-acetoxy-19-norpregn-4-ene-3,20-dione.

14. A method for remyelination in post-menopausal women comprising treating said post-menopausal women with a pharmaceutically effective dosage of a progestin compound which exerts binding to progesterone receptors and elicits progesterone-receptor-induced biological responses without interacting with the androgen receptor and without inducing androgenic or glucocorticoid biological responses selected from the group consisting of 16-methylene-17α-acetoxy-19-norpregn-4-ene-3,20-dione, 18-methyl Nosterone, nomegestrol acetate, trimegestone, and promegestone at a dosage of an effective amount for remyelination in said post-menopausal women comprising 100 to 450 μg/day, and simultaneously providing a predetermined dosage of natural estradiol.

15. A method for remyelination exhibited in a condition selected from the group consisting of Multiple Sclerosis, Alzheimer’s Disease, and Parkinson’s Disease in a patient comprising treating said patient with a pharmaceutically effective dosage of a progestin compound which exerts binding to progesterone receptors and elicits progesterone-receptor-induced biological responses selected from the group consisting of 16-methylene-17α-acetoxy-19-norpregn-4-ene-3,20-dione, 18-methyl Nosterone, nomegestrol acetate, trimegestone, and promegestone without interacting with the androgen receptor and without inducing androgenic or glucocorticoid biological responses at a dosage comprising 100 to 450 μg/day as an effective amount for remyelination and sufficient to reduce relapses of said conditions.

* * * * *